Medicure Inc.
Loading stock data...
Stock Performance
Price History
-
Drag to select time range
-
Market Data
Market Cap
13.4M
P/E Ratio
-
52-Week High
-
52-Week Low
-
Avg Volume
-
Beta
-
Forward P/E
-
Dividend Yield
-
EV/Revenue
-
Price/Book
-
Business Overview
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.
Healthcare
Drug Manufacturers - Specialty & Generic
TSXV
Key Financial Metrics
21.9M
Revenue
-1.0M
Net Income
C$-0.10
EPS (Diluted)
638,000
Free Cash Flow
Profitability
Gross Margin
59.7%
Operating Margin
-12.5%
Net Profit Margin
-4.7%
EBITDA
1.5M
Returns & Efficiency
Return on Assets (ROA)
-3.5%
Return on Equity (ROE)
-5.0%
Dividend Yield
-
Payout Ratio
-
Financial Health
Total Assets
29.7M
Total Debt
874,000
Debt to Equity
0.04x
Current Ratio
1.89
Company Info
| Industry | Drug Manufacturers - Specialty & Generic |
| HQ | Winnipeg, Canada |
| Fiscal Year End | 1735603200 |
| Currency | CAD |
| Website | www.medicure.com |
Peers
Bausch + Lomb Corporation
BLCO.TO
7.9B
P/E: --
Bausch Health Companies Inc.
BHC.TO
2.5B
P/E: 12.0
Extendicare Inc.
EXE.TO
2.5B
P/E: 23.7
Sienna Senior Living Inc.
SIA.TO
2.2B
P/E: 53.2
Cronos Group Inc.
CRON.TO
1.4B
P/E: 24.1
Tilray Brands, Inc.
TLRY.TO
1.2B
P/E: --
WELL Health Technologies Corp.
WELL.TO
1.1B
P/E: --
Knight Therapeutics Inc.
GUD.TO
631.8M
P/E: --
Insider Activity
Sentiment
Bullish
Shares Bought
10,000
Shares Sold
0
Total Transactions
1
SEDAR+ Filings
View All Filings8
Annual Reports
24
Quarterly Reports
26
MD&A
89
News Releases
17
Material Changes
15
Governance
58
Certifications
33
Other
Interactive Charts
Company Profile
General Information
| Company Name | Medicure Inc. |
| Ticker | MPH.V |
| Exchange | TSXV |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Headquarters | Winnipeg, Canada |
| Fiscal Year End | 1735603200 |
| Currency | CAD |
| Website | www.medicure.com |
Financial Summary
| Market Cap | 13.4M |
| Revenue | 21.9M |
| Net Income | -1.0M |
| P/E Ratio | N/A |
| EPS (Diluted) | C$-0.10 |
| Net Margin | -4.7% |
| ROE | -5.0% |
| Dividend Yield | N/A |
Business Description
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.